VIVES is a multi-sector fund that invests in projects with a positive societal impact
GreenWatt, founded in Belgium in 2004 as a spin-off from the Catholic University of Louvain (UCLouvain), designs, develops and markets locally integrated "key-to-door" biogas plants for the food and...
iTeos Therapeutics targets the tumor microenvironment to boost immune cell efficiency in cancer eradication.
Immunotherapy is a revolutionary approach to cancer treatment that aims to educate the...
IntoPIX is an independent and innovative technology provider with world-class expertise and knowledge in video processing and compression, cryptography, high performance computing and microelectronics...
Pierre-Antoine Mariage, co-CEO Botalys :
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Pierre Blondeau, CEO Upstreem :
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Issam Doghri, professor at UCLouvain and co-founder of e-Xstream engineering:
"I developed a first version of a software (Digimat- for digital materials) and I was thinking about ways to make it...
- Proposer Des Thérapies Cellulaires Innovantes Axées Sur Le Foie Pour Le Marché Japonais -
Promethera® Biosciences SA ("Promethera®") et MEDIPAL HOLDINGS CORP. ("MEDIPAL") ont annoncé aujourd’hui la
Belgium – 5 November 2019 – Syndesi Therapeutics SA, a biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced
L’étude met en avant les avantages potentiels de ce traitement pour les troubles orthopédiques rares chez l'enfant.
Mont-Saint-Guibert, Belgique, le 2 octobre 2019 : Novadip Biosciences («Novadip» ou